The Technical Analyst
NextCure Inc [NXTC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
NextCure Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-10.42% $1.290
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 36.09 mill |
| EPS: | -2.25 |
| P/E: | -0.570 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 27.97 mill |
| Avg Daily Volume: | 0.285 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.570 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.570 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.233 (-81.96%) $-1.057 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.063 - 1.517 ( +/- 17.60%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Shaw Kevin G. | Buy | 93 900 | Employee Stock Option (Right to Buy) |
| 2024-03-29 | Richman Michael | Buy | 244 400 | Employee Stock Option (Right to Buy) |
| 2024-03-29 | Myint Han | Buy | 93 900 | Employee Stock Option (Right to Buy) |
| 2024-03-29 | Mayer Timothy | Buy | 93 900 | Employee Stock Option (Right to Buy) |
| 2024-03-29 | Langermann Sol | Buy | 93 900 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 6 167 538 | Sell: 82 463 |
Forecast:
16:00 - $1.310
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.310
Forecast 2: 16:00 - $1.310
Forecast 3: 16:00 - $1.310
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.290 (-10.42% ) |
| Volume | 0.156 mill |
| Avg. Vol. | 0.285 mill |
| % of Avg. Vol | 54.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NXTC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Latest Press Releases
2024-04-24 16:05:00 - Press Release
Nextcure To Present Phase 1b Data Of Nc410 In Combination With Pembrolizumab At Asco 2024
Beltsville, md., april 24, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator eric s.
2024-04-08 07:00:00 - Press Release
Nextcure And Lcb Present Preclinical Data On B7-h4 Antibody Drug Conjugate At Aacr 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for lncb74 poster presentation highlights strong safety and pharmacokinetic profiles for lncb74
2024-04-04 07:05:00 - Press Release
Nextcure Appoints Dr. Rakesh Dixit To Scientific Advisory Board
Beltsville, md., april 04, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of rakesh dixit, phd, to its scientific advisory board. as an accomplished product developer whose expertise is focused on antibody-drug conjugates (adcs), dr. dixit will support nextcure in its efforts to build and develop its proprietary adcs, including lncb74 directed to b7-h4.
2024-04-02 07:00:00 - Press Release
Nextcure To Present At 23rd Annual Needham Virtual Healthcare Conference
Beltsville, md., april 02, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd annual needham virtual healthcare conference on thursday, april 11th, at 12:45 pm et.
2024-03-21 08:55:00 - Press Release
Nextcure Provides Business Update And Reports Full Year 2023 Financial Results
Beltsville, md. – march 21, 2024, march 21, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update and reported full year 2023 financial results.
Latest News
2024-04-02 07:00:00 - GlobeNewsWire
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.
2024-03-23 06:00:00 - InvestorPlace
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.
2023-12-25 11:16:08 - Zacks Investment Research
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2023-12-15 12:46:47 - Zacks Investment Research
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
2023-11-20 07:00:00 - GlobeNewsWire
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.
2023-11-07 13:32:16 - Zacks Investment Research
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-08-31 07:00:00 - GlobeNewsWire
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Monday, September 11th, at 5:00 pm ET.
2023-05-09 07:00:00 - GlobeNewsWire
NextCure to Present at the JMP Securities Life Sciences Conference
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
2023-04-11 07:00:00 - GlobeNewsWire
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
2023-02-07 07:00:00 - GlobeNewsWire
NextCure to Present at SVB Securities Global Biopharma Conference
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.